Pfizer is pulling its sickle cell disease (SCD) treatment voxelotor (Oxbryta) from global markets after data review showed an imbalance in deaths among patients taking the drug. "The overall benefit ...

Bluebird Bio is making progress on the launch of its three approved gene therapies but appears to be trailing Vertex in its competition to attract patients to their respective treatments for sickle ...

This article is part of a Health Affairs Forefront series on “The Future of Sickle Cell Disease Research and Care” with support from the American Society of Hematology. The articles in the series are ...

Given the remarkable advances seen with gene therapies for sickle cell disease (SCD), it may seem counterintuitive to suggest the space may be in need of more therapies that have already been ...

McKesson Corporation’s MCK dedicated business focused on supporting the commercialization of cell and gene therapies, InspiroGene, has been selected by Vertex Pharmaceuticals Incorporated VRTX to ...

This article is part of a Health Affairs Forefront series on “The Future of Sickle Cell Disease Research and Care” with support from The American Society of Hematology. The articles in the series are ...

Despite some recent setbacks to its sickle cell disease (SCD) pipeline, Pfizer is plowing ahead in improving education around the disease. The Big Pharma’s U.K. branch unveiled on Monday the first ...

ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Visit NAP.edu/10766 to get more information about this book, to buy it in print, or to download it as a free PDF. Sickle cell disease (SCD) is a group of inherited blood disorders that affects ...